Pycnogenol for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Pycnogenol for Health & Longevity

Created on 08/10/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A standardized French maritime pine bark extract, made to a fixed specification most plant products do not match. Best-supported effect: modest lowering of fasting blood sugar and the three-month blood sugar average. Vessel-lining, heavy-leg and erectile effects rest on smaller studies. It is unusually well tolerated; stomach upset is the main complaint. Evidence quality limits it, not biology. (Full Review)

Protocol

Standard maintenance dose
100–200 mg per day
Lower end covers the metabolic and endothelial endpoints; 150–200 mg is where the inflammation and cognitive signals appear.
Split rather than single dosing
100 mg twice daily
Or 50 mg three times daily; absorbed constituents have plasma half-lives of only two to six hours.
Best time of day
With meals, larger portion in the morning
The α-glucosidase effect is only useful with a carbohydrate-containing meal; no trial has compared timing directly.
Time to effect
Fasting glucose
4–12 weeks
The metabolic effects are the quickest; nothing here works acutely.
Endothelial function
8 weeks
Vascular measures take longer than the metabolic ones.
Skin properties
12 weeks
Skin measures take the longest; cognitive measures fall in the same one-to-three-month window.

Benefits

Contraindications
  • Pregnancy in the first and second trimesters, and any dose above 30 mg daily at any stage of pregnancy; breastfeeding at any dose
  • Solid organ transplant recipients on maintenance immunosuppression, and active autoimmune disease on biologic therapy, without specialist supervision
  • Within 14 days of a scheduled surgical or dental procedure, or a diagnosed bleeding disorder or platelet count below 100 × 109/L
  • eGFR below 45 mL/min/1.73 m², or Child-Pugh Class B or C liver impairment
  • Children under 18 outside a supervised clinical context
  • Known pine, conifer or conifer-pollen allergy
    •
Key Interactions
  • Antidiabetic medications (insulin, sulfonylureas, meglitinides)
  • Antihypertensive medications (ACE inhibitors, ARBs, calcium channel blockers, thiazide diuretics)
  • Anticoagulants and antiplatelets (warfarin, direct oral anticoagulants, clopidogrel, ticagrelor, low-dose aspirin)
  • Immunosuppressants (tacrolimus, ciclosporin, mycophenolate, azathioprine, biologics)
  • Over-the-counter NSAIDs (ibuprofen, naproxen, diclofenac, aspirin)
  • Over-the-counter antacids and acid reducers (proton pump inhibitors, H2 blockers)
  • Nitric oxide precursor supplements (L-arginine, L-citrulline, dietary nitrate, arginine silicate)
  • Blood-pressure-lowering supplements (magnesium, potassium, hibiscus, garlic, coenzyme Q10, omega-3, taurine)
  • Glucose-lowering supplements (berberine, chromium picolinate, alpha-lipoic acid, cinnamon, inositol)
  • Antiplatelet supplements (high-dose fish oil, Ginkgo biloba, garlic, high-dose vitamin E, nattokinase, curcumin, bromelain)
  • Overlapping polyphenol extracts (grape seed, Pinus massoniana)
    •

Risk & Side Effects

  • High: Gastrointestinal discomfort
    •
  • Medium: Additive blood-glucose lowering; additive blood-pressure lowering; dizziness and headache
    •
  • Low: Increased bleeding tendency (conflicted); allergic and skin reactions; mouth ulcers and altered taste; immune stimulation in autoimmune disease
    •
  • Speculative: Long-term safety beyond six months; use in pregnancy and lactation; interference with drug metabolism; rhabdomyolysis after unaccustomed exertion
    •

Monitoring

Marker Target Why
Fasting blood glucose 75–86 mg/dL Tracks the best-replicated effect of the compound
HbA1c 4.8–5.3% Confirms the glucose effect over a three-month window
Fasting insulin 2–5 µIU/mL Distinguishes a true insulin-sensitivity gain from carbohydrate malabsorption
High-sensitivity CRP Below 0.5 mg/L The inflammation marker with pooled trial data behind it
Home blood pressure, seated 110–125 / 70–80 mmHg Detects both the contested benefit and the additive-hypotension risk
ApoB, with LDL cholesterol ApoB below 80 mg/dL; LDL 70–100 mg/dL A particle count is more informative than cholesterol alone
Triglyceride to HDL cholesterol ratio Below 2.0 A single composite readout of metabolic direction
Complete blood count with platelets Platelets 175–350 × 109/L Baseline for the theoretical bleeding-risk concern
eGFR with serum creatinine Above 90 mL/min/1.73 m² Elimination is predominantly renal and untested in impairment
ALT 10–26 U/L (men), 8–22 U/L (women) Screens for botanical-associated liver injury

Cadence: Safety and additive-effect checks daily for the first 2 weeks after starting or any dose increase; the full biomarker panel at 12 weeks; then every 6 months, with a repeat measurement four weeks into any planned washout.

Qualitative Assessment

  • Leg heaviness, aching or swelling at the end of the day
  • Night-time leg cramps and restless-leg sensation, by frequency per week
  • Joint stiffness on waking and joint pain with load, plus anti-inflammatory tablets taken per week
  • Skin hydration, firmness and visible pigmentation, by standardized photographs at baseline and 12 weeks
  • Exercise recovery: perceived soreness 24 and 48 hours after a hard session, and cramp frequency during training
  • Energy through the afternoon, and cognitive clarity in demanding work
  • Seasonal allergy symptom burden in eye and nasal domains, across a full season
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.